Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.
Identifieur interne : 001568 ( PubMed/Checkpoint ); précédent : 001567; suivant : 001569Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.
Auteurs : C L Gervason [France] ; P R Pollak ; P. Limousin ; J E PerretSource :
- Clinical neuropharmacology [ 0362-5664 ] ; 1993.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Apomorphine.
- chemical , pharmacology : Apomorphine, Domperidone.
- drug effects : Movement.
- physiology : Movement.
- physiopathology : Parkinson Disease.
- Aged, Female, Humans, Injections, Subcutaneous, Male, Middle Aged.
Abstract
We performed a crossover study of apomorphine-induced motor response reproducibility in 10 parkinsonian patients with the "on-off" phenomenon. On 2 separate days, each patient received two successive identical s.c. apomorphine injections, the second injection being randomly administered either 10 or 80 min after the end of the first apomorphine-induced motor benefit. Latency (12.3 +/- 4.5 min) and duration (61.9 +/- 13.3 min) of motor effects were similar in all tests. A transient worsening of the parkinsonian state after a motor improvement induced by apomorphine occurred in most of the patients. Therefore, the duration and severity of the "off" period after a motor improvement does not seem to influence the efficacy of a second apomorphine administration.
PubMed: 8477407
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:8477407Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.</title><author><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C L" last="Gervason">C L Gervason</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology U 318, Joseph Fourier University of Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology U 318, Joseph Fourier University of Grenoble</wicri:regionArea><wicri:noRegion>Joseph Fourier University of Grenoble</wicri:noRegion><wicri:noRegion>Joseph Fourier University of Grenoble</wicri:noRegion></affiliation></author><author><name sortKey="Pollak, P R" sort="Pollak, P R" uniqKey="Pollak P" first="P R" last="Pollak">P R Pollak</name></author><author><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P" last="Limousin">P. Limousin</name></author><author><name sortKey="Perret, J E" sort="Perret, J E" uniqKey="Perret J" first="J E" last="Perret">J E Perret</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8477407</idno><idno type="pmid">8477407</idno><idno type="wicri:Area/PubMed/Corpus">001719</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001719</idno><idno type="wicri:Area/PubMed/Curation">001678</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001678</idno><idno type="wicri:Area/PubMed/Checkpoint">001678</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001678</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.</title><author><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C L" last="Gervason">C L Gervason</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology U 318, Joseph Fourier University of Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology U 318, Joseph Fourier University of Grenoble</wicri:regionArea><wicri:noRegion>Joseph Fourier University of Grenoble</wicri:noRegion><wicri:noRegion>Joseph Fourier University of Grenoble</wicri:noRegion></affiliation></author><author><name sortKey="Pollak, P R" sort="Pollak, P R" uniqKey="Pollak P" first="P R" last="Pollak">P R Pollak</name></author><author><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P" last="Limousin">P. Limousin</name></author><author><name sortKey="Perret, J E" sort="Perret, J E" uniqKey="Perret J" first="J E" last="Perret">J E Perret</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="ISSN">0362-5664</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Apomorphine (administration & dosage)</term><term>Apomorphine (pharmacology)</term><term>Domperidone (pharmacology)</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Movement (drug effects)</term><term>Movement (physiology)</term><term>Parkinson Disease (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term><term>Domperidone</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Movement</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Movement</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed a crossover study of apomorphine-induced motor response reproducibility in 10 parkinsonian patients with the "on-off" phenomenon. On 2 separate days, each patient received two successive identical s.c. apomorphine injections, the second injection being randomly administered either 10 or 80 min after the end of the first apomorphine-induced motor benefit. Latency (12.3 +/- 4.5 min) and duration (61.9 +/- 13.3 min) of motor effects were similar in all tests. A transient worsening of the parkinsonian state after a motor improvement induced by apomorphine occurred in most of the patients. Therefore, the duration and severity of the "off" period after a motor improvement does not seem to influence the efficacy of a second apomorphine administration.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8477407</PMID><DateCreated><Year>1993</Year><Month>05</Month><Day>25</Day></DateCreated><DateCompleted><Year>1993</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>1993</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>113-9</MedlinePgn></Pagination><Abstract><AbstractText>We performed a crossover study of apomorphine-induced motor response reproducibility in 10 parkinsonian patients with the "on-off" phenomenon. On 2 separate days, each patient received two successive identical s.c. apomorphine injections, the second injection being randomly administered either 10 or 80 min after the end of the first apomorphine-induced motor benefit. Latency (12.3 +/- 4.5 min) and duration (61.9 +/- 13.3 min) of motor effects were similar in all tests. A transient worsening of the parkinsonian state after a motor improvement induced by apomorphine occurred in most of the patients. Therefore, the duration and severity of the "off" period after a motor improvement does not seem to influence the efficacy of a second apomorphine administration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gervason</LastName><ForeName>C L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology U 318, Joseph Fourier University of Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Limousin</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Perret</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5587267Z69</RegistryNumber><NameOfSubstance UI="D004294">Domperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004294" MajorTopicYN="N">Domperidone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8477407</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P" last="Limousin">P. Limousin</name><name sortKey="Perret, J E" sort="Perret, J E" uniqKey="Perret J" first="J E" last="Perret">J E Perret</name><name sortKey="Pollak, P R" sort="Pollak, P R" uniqKey="Pollak P" first="P R" last="Pollak">P R Pollak</name></noCountry><country name="France"><noRegion><name sortKey="Gervason, C L" sort="Gervason, C L" uniqKey="Gervason C" first="C L" last="Gervason">C L Gervason</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001568 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001568 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:8477407
|texte= Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:8477407" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |